Publicaciones científicas

/cun/investigacion/publicaciones-cientificas/areaMain/02
  • Delta-24-RGD combined with radiotherapy exerts a potent antitumor effect in diffuse intrinsic pontine glioma and pediatric high grade glioma models

    Martinez-Velez N (1,2,3), Marigil M (1,2,3,4), García-Moure M (1,2,3), Gonzalez-Huarriz M (1,2,3), Aristu JJ (1,5), Ramos-García LI (5), Tejada S (1,2,6), Díez-Valle R (1,2,6), Patiño-García A (1,2,3), Becher OJ (7), Gomez-Manzano C (8,9), Fueyo J (8,10), Alonso MM (11,12,13).

    (1) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (2) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (3) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.
    (4) Division of Neurosurgery, Lariboisière University Hospital, 2 Rue Ambroise Paré, 75475, Paris, cedex 10, France.
    (5) Department of Radiation Oncology, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (6) Department of Neurosurgery, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.
    (7) Department of Pediatrics, Northwestern University and Division of Pediatric Hematology-Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, USA.
    (8) Department of Genetics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (9) Department of NeuroOncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (10) Department of Neurosurgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
    (11) The Health Research Institute of Navarra (IDISNA), Pamplona, Navarra, Spain.
    (12) Program in Solid Tumors, Foundation for the Applied Medical Research, Pamplona, Navarra, Spain.
    (13) Department of Pediatrics, Clínica Universidad de Navarra, University of Navarra, CIMA Building, Avd. Pio XII, 55, Pamplona, Spain.

    Acta Neuropathologica Communications 29 de ABRIL de 2019

  • Identification of mutations associated with acquired resistance to sunitinib in renal cell-cancer

    Elgendy M (1,2), Fusco JP (3,4), Segura V (5), Lozano MD (4,6,7), Minucci S (1,8), Echeveste JI (4,6), Gurpide A (3,4), Andueza M (3,4), Melero I (4,7,9), Sanmamed MF (3,4), Ruiz MR (3,4), Calvo A (4,10), Pascual JI (4,11), Velis JM (4,11), Miñana B (4,11), Valle RD (4,12), Pio R (4,7,13), Agorreta J (4,7,13), Abengozar M (4,6), Colecchia M (14), Brich S (14), Renne SL (14), Guruceaga E (5), Patiño-García A (4,13,15), Perez-Gracia JL (3,4,7).

    (1) Department of Experimental Oncology, European Institute of Oncology (IEO), Milan, Italy.
    (2) Department of Pharmaceutical Chemistry, University of Vienna, Vienna, Austria.
    (3) Department of Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
    (4) Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
    (5) IDISNA and Bioinformatics Unit, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Navarra, Spain.
    (6) Pathology Department, Clinica Universidad de Navarra, Pamplona, Spain.
    (7) Centro de Investigación Biomédica en Red de Cáncer (CIBERONC).
    (8) Department of Biosciences, University of Milan, Milan, Italy.
    (9) Department of Immunology, Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (10) Department of Histology and Pathology, School of Medicine, University of Navarra, Pamplona, Navarra, Spain.
    (11) Department of Urology, Clinica Universidad de Navarra, Pamplona and Madrid, Spain.
    (12) Department of Neurosurgery, University Clinic of Navarra, Pamplona, Spain.
    (13) Program in Solid Tumors. Center for Applied Medical Research (CIMA), Pamplona, Spain.
    (14) Department of Diagnostic Pathology and Laboratory Medicine, Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy.
    (15) Department of Pediatrics and Clinical Genetics, Clinica Universidad de Navarra, Pamplona, Spain.

    International Journal of Cancer 08 de MARZO de 2019

  • HGF-rs12536657 and Ocular Biometric Parameters in Hyperopic Children, Emmetropic Adolescents, and Young Adults

    Barrio-Barrio J (1), Bonet-Farriol E (1), Galdós M (2), Noval S (3), Pueyo V (4), Breeze CE (5), Santos JL (6), Alfonso-Bartolozzi B (1), Recalde S (1), Patiño-García A (7).

    (1) Department of Ophthalmology, Clínica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.
    (2) Department of Ophthalmology, Hospital de Cruces, 48903 Bilbao, Spain.
    (3) Department of Ophthalmology, Hospital Universitario La Paz, Autonomous University, IdiPaz, 28046 Madrid, Spain.
    (4) Aragon Institute for Health Research (IIS Aragón), Ophthalmology Department, Miguel Servet University Hospital, 50009 Zaragoza, Spain.
    (5) UCL Cancer Institute, University College London, London WC1E 6BT, UK.
    (6) Department of Nutrition, Diabetes and Metabolism, School of Medicine, Pontificia Universidad Católica de Chile, 8330077 Santiago, Chile.
    (7) Department of Pediatrics and Clinical Genetics Unit, Clínica Universidad de Navarra, Navarra Institute for Health Research (IdiSNA), 31008 Pamplona, Spain.

    Journal of Ophthalmology 03 de FEBRERO de 2019

  • Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models

    Collantes M (1,2), Martínez-Vélez N (3), Zalacain M (3,2), Marrodán L (3,2), Ecay M (4), García-Velloso MJ (1,2), Alonso MM (3,2), Patiño-García A (3,2), Peñuelas I (5,6,7).

    (1) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (2) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (3) Departamento de Pediatría, Clínica Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (4) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (5) Servicio de Medicina Nuclear, Clínica Universidad de Navarra, Avenida Pío XII, 36 31008, Pamplona, Spain.
    (6) Small Animal Imaging Research Unit, CIMA, Universidad de Navarra, Avenida Pío XII, 31008, Pamplona, Spain.
    (7) IdisNA, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    BMC Cancer 29 de NOVIEMBRE de 2018

  • Liquid Biopsy: From Basic Research to Clinical Practice

    Macías M (1), Alegre E (2), Díaz-Lagares A (3), Patiño A (2), Pérez-Gracia JL (2), Sanmamed M (4), López-López R (3), Varo N (2), González A (5).

    (1) Clínica Universidad de Navarra, Pamplona, Spain.
    (2) Clínica Universidad de Navarra, Pamplona, Spain; The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.
    (3) Translational Medical Oncology (Oncomet), Health Research Institute of Santiago (IDIS), University Clinical Hospital of Santiago (CHUS), CIBERONC, Santiago de Compostela, Spain; Roche-CHUS Joint Unit, University Clinical Hospital of Santiago (CHUS), Santiago de Compostela, Spain.
    (4) Yale University School of Medicine, New Haven, CT, United States.
    (5)Clínica Universidad de Navarra, Pamplona, Spain; The Health Research Institute of Navarra (IDISNA), Pamplona, Spain.

    Advances in Clinical Chemistry 02 de ENERO de 2018

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra